Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla.
GlobeNewsWire9/1/2026Neutral
AXGN
Axogen IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$2.60B
P/E Ratio
—
EPS
$-0.67
Beta
1.16
52W High
$52.91
52W Low
$15.27
50-Day MA
$45.19
200-Day MA
$37.55
Dividend Yield
—
Profit Margin
-13.40%
Forward P/E
111.11
PEG Ratio
99.04
About Axogen Inc
AxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.
Fundamentals
| Revenue (TTM) | $251.17M |
| Gross Profit (TTM) | $187.26M |
| EBITDA | $-5.97M |
| Operating Margin | -3.09% |
| Return on Equity | -18.20% |
| Return on Assets | -3.15% |
| Revenue/Share (TTM) | $5.07 |
| Book Value | $4.78 |
| Price-to-Book | 9.88 |
| Price-to-Sales (TTM) | 10.33 |
| EV/Revenue | 9.71 |
| EV/EBITDA | 4083.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 23.10% |
| Shares Outstanding | $53.76M |
| Float | $52.62M |
| % Insiders | 2.16% |
| % Institutions | 99.14% |
Historical Volatility
HV 10-Day
35.25%
HV 20-Day
49.50%
HV 30-Day
49.78%
HV 60-Day
47.30%
HV Rank
57.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($53.90 target)
2
Strong Buy7
BuyLatest News
Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel
Axogen is transforming from a niche tissue supplier into a comprehensive nerve care platform, underpinned by FDA approval, stronger reimbursement, and expanding clinical evidence. Q2 2026 revenue grew 23.1% to $69.7M, with raised full-year guidance and strong elective market traction, though gross margin declined due to product mix and biologic costs. Avance's FDA biologic approval grants 12 years of exclusivity, regulatory credibility, and improved payer coverage, positioning AXGN as a category leader with significant market opportunity.
Seeking Alpha8/3/2026Positive
Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript
Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript
Seeking Alpha7/29/2026Neutral
AxoGen Q2 Earnings Call Highlights
AxoGen NASDAQ: AXGN reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing growth of at least 24%, while lowering its gross-margin expectation to at least 73% due to product-mix changes tied to faster-than-expected growth in breast reconstruction.
MarketBeat7/29/2026Neutral
AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago.
Zacks Investment Research7/29/2026Positive
Axogen, Inc. Reports Second Quarter 2026 Financial Results
ALACHUA, Fla. and TAMPA, Fla.
GlobeNewsWire7/29/2026Neutral
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
GlobeNewsWire7/15/2026Neutral
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen NASDAQ: AXGN President and CEO Michael Dale said the company's growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified.
MarketBeat5/14/2026Positive
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla.
GlobeNewsWire4/30/2026Neutral
AxoGen (AXGN) Q1 Earnings Lag Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago.
Zacks Investment Research4/28/2026Negative
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AXGN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026